ANXV

BIOLOGICAL3 trials

Sponsors

Annexin Pharmaceuticals AB

Conditions

HealthyNon-Proliferative Diabetic RetinopathyRetinal Vein Occlusion

Phase 1

First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers

CompletedNCT04850339

Annexin Pharmaceuticals ABHealthy

Start: 2020-12-21End: 2021-10-27Updated: 2022-05-16

Phase 2

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion

CompletedNCT05532735

Annexin Pharmaceuticals ABRetinal Vein Occlusion

Start: 2022-08-24End: 2024-11-11Updated: 2024-12-11

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion

RecruitingNCT07259928

Annexin Pharmaceuticals ABNon-Proliferative Diabetic Retinopathy, Retinal Vein Occlusion

Start: 2025-11-07End: 2026-07-31Target: 12Updated: 2025-12-02